| | Reference | Patients () | treatment | Surgery (%) | R0 resection (%) | PCR (%) | Survival rate (%) or median survival (mo) |
| | Lowy et al. [21] | 24 | 5-FU + 45 EBRT | 83 | 75 | 11 | NS | | Wydmański et al. [22] | 40 | 5-FU + LV + 45 Gy EBRT | 80 | 75 | 18 | 63% (2 years) | | Allal et al. [23] | 19 | 5-FU + LV + C + 38.4 Gy | 100 | NS | 5 | 35% (5 years) | | Ajani et al. [24] | 34 | 5-FU, LV, C + 45 Gy EBRT, 5-FU | 85 | 70 | 30 | 33.7 months | | Ajani et al. [25] | 41 | 5-FU, C, P + 45 Gy EBRT, 5-FU, P | 98 | 78 | 20 | NS | | Ajani et al. [26] | 49 | 5-FU, LV, C + 45 Gy EBRT, 5-FU, P | 83 | 77 | 26 | 23.2 months | | Stahl et al. [27] | 126 | 5-FU, LV, C + surgery versus 5-FU, LV, C + 30 Gy, C, etoposide + surgery | 88 versus 82 | 69 versus 72 | 2.0 versus 15.6 | 27.7 versus 47.4 (3 years) | | Inoue et al. [29] | 12 | S-1, 50 Gy EBRT | 100 | 92 | 17 | 58.3 (3 years) | | Lee et al. [30] | 12 | S-1,oxaliplaitin, 41.4 Gy EBRT | 100 | 92 | 8 | NS | | Trip et al. [31] | 25 | Carboplatin, P + 45 Gy EBRT | 96 | 72 | 16 | NS | | van Hagen et al. [32] | 366 | Carboplatin, P, 41.4 Gy EBRT + surgery versus surgery alone | 94 versus 99 | 92 versus 69 | 29 versus 49 | 49, 4 mos versus 24.0 mos |
|
|
